TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company’s product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California.

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)’s Financial Overview

TRACON Pharmaceuticals, Inc. (NASDAQ) declined -2.83% yesterday to close its trading session at $1.03. The company has 1 year Price Target of $5.6. TRACON Pharmaceuticals, Inc. has 52-Week high of $3.2 and 52-Week Low of $0.5. The stock touched its 52-Week High on 3.20 and 52-Week Low on 0.50. The stock traded with the volume of 330955 shares yesterday. The firm shows the market capitalization of $31.7 Million.

TRACON Pharmaceuticals, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.3/share against the analyst consensus estimate of $-0.28/share. The difference between the actual and expected EPS is $-0.02 a share with a surprise factor of -7.1%.

The firm is trading with SMA20 of 12.92 Percent, SMA50 of 8.74 Percent and SMA200 of -45.83 percent. TRACON Pharmaceuticals, Inc. has P/S value of 10.57 while its P/B value stands at 1.07. Similarly, the company has Return on Assets of -66.4 percent, Return on Equity of -108 percent and Return on Investment of -74.6 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 4 analysts offering 12-month price forecasts for TRACON Pharmaceuticals Inc have a median target of 6.20, with a high estimate of 9.00 and a low estimate of 1.00. The median estimate represents a +501.94% increase from the last price of 1.03.

TRACON Pharmaceuticals, Inc. is estimated to report earnings on 02/27/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.37.


First Republic Bank operates as a commercial bank offering private banking, business banking, real estate lending and wealth management services in California. The bank’s services are catered to accounting firms, architecture and design, business management firms, entertainment/media, family offices, hedge funds, independent schools, investment firms, law firms, medical firms, non-profit organizations, private equity funds/firms, property management firms, venture capital firms and etc. Services offered by First Republic include asset allocation, trust administration, custody, asset management, brokerage, private placements, ATM rebate checking, money market checking, passbook savings, and certificates of deposit and etc. The Company’s product include family mortgages, co-op and condominium loans, home equity lines of credit, bridge loans, and construction-to-permanent loans; commercial lending and personal lending. First Republic Bank is headquartered in San Francisco, California.


The 22 analysts offering 12-month price forecasts for First Republic Bank have a median target of 98.00, with a high estimate of 115.00 and a low estimate of 92.00. The median estimate represents a -2.52% decrease from the last price of 100.53.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, FIRST REPUBLIC BANK has a Consensus Recommendation of 2.13. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock declined -0.13% and closed its last trading session at $100.53. The company has the market capitalization of $16.8 Billion. The stock has 52-week high of $106.75 and 52-Week low of $79.42. The firm touched its 52-Week high on 106.75 and 52-Week low on 79.42. The company has volume of 1.27 Million shares. The company has a total of 167.11 Million shares outstanding.

FIRST REPUBLIC BANK (NYSE) in the last quarter reported its actual EPS of $1.29/share where the analyst estimated EPS was $1.23/share. The difference between the actual and Estimated EPS is $0.06. This shows a surprise factor of 4.9 percent.

The company has YTD performance of 15.68 percent. Beta for FIRST REPUBLIC BANK stands at 0.9 while its ATR (average true range) is 2.02. The company has Weekly Volatility of 1.41%% and Monthly Volatility of 2.03%%.

FIRST REPUBLIC BANK has distance from 20-day Simple Moving Average (SMA20) of 5.57%, Distance from 50-Day Simple Moving Average of 9.56 percent and Distance from 200-Day Simple Moving Average of 4.49%.

The Company currently has ROA (Return on Assets) of 0.8 percent, Return on Equity (ROE) of 10.5 Percent and Return on Investment (ROI) of 23.3% with Gross margin of 0 percent and Operating & Profit margin of 74.5% and 24.7% respectively.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *